Subscribe to RSS
DOI: 10.1160/TH09-10-0685
Risk of recurrent venous thromboembolism after a first oestrogen-associated episode
Data from the REVERSE cohort study Financial support:The REVERSE study was funded by the Canadian Institutes of Health Research (grant no. MOP 64319) and bioMérieux (through an unrestricted research grant). Dr. Grégoire Le Gal was the recipient of a University of Ottawa International Fellowship. Dr. Marc Carrier is a recipient of a Canadian Institute for Health Research Fellowship. Dr. Marc Rodger is a Heart and Stroke Foundation of Canada Career Scientist and has received support from the Ontario Ministry of Research and Innovation. Dr. Susan Kahn is a recipient of a Clinical Investigator Award from the Fonds de la Recherche en Santé du Québec. Dr. Phil Wells is a recipient of Canada Research Chair. Dr. Mark Crowther holds a Career Investigator Award from the Heart and Stroke Foundation.Publication History
Received:
03 October 2009
Accepted after major revision:
15 April 2010
Publication Date:
23 November 2017 (online)
Summary
The use of exogenous oestrogen in women with otherwise unprovoked venous thromboembolism (VTE) could be considered sufficient explanation to classify VTE as provoked if the risk of recurrent VTE after 3–6 months of anticoagulant treatment is similar to the risk of recurrent VTE observed after a surgery or prolonged immobilisation. Our objective was to assess the risk of recurrent VTE in women after a first unprovoked episode on oestrogen. The REVERSE study is a cohort study of patients with a first unprovoked VTE treated with anticoagulant treatment for 5–7 months. The risk of recurrent VTE during follow-up was compared between women users and non users of oestrogen at the time of index VTE. Among the 646 patients included, 314 were women, of them 67 were current users of oestrogen at the time of their VTE: 49 were on oral contraceptives and 18 on post-menopausal hormone replacement therapy (HRT). No significant association was found between oestrogen exposure, either oral contraceptives or HRT, and a lower risk of recurrent VTE after adjustment for age, or analysis restricted to women in the same age range as oestrogen contraceptives and HRT users, respectively. The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE. However, this risk is not significantly lower than in women whose VTE was not related to oestrogen use.
-
References
- 1 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
- 2 Oger E, Lacut K, Le Gal G. et al. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 2006; 4: 793-799.
- 3 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
- 4 Palareti G, Cosmi B, Legnani C. et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
- 5 Kyrle PA, Minar E, Bialonczyk C. et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-2563.
- 6 Agnelli G, Prandoni P, Santamaria MG. et al. the Warfarin Optimal Duration Italian Trial Investigators. Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. N Engl J Med 2001; 345: 165-169.
- 7 Piccioli A, Lensing AWA, Prins MH. et al., for the SOMIT investigators group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 884-889.
- 8 Christiansen SC, Cannegieter SC, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
- 9 Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443-1450.
- 10 Canonico M, Plu-Bureau G, Lowe GD. et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Br Med J 2008; 336: 1227-1231.
- 11 Rosendaal F. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
- 12 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
- 13 Rodger MA, Kahn SR, Wells PS. et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMA J 2008; 179: 417-426.
- 14 Le Gal G, Kovacs MJ, Carrier M. et al. Validation of a diagnostic approach to exclude recurrent venous thromboembolism. J Thromb Haemost 2009; 7: 752-759.
- 15 Baglin T, Luddington R, Brown K. et al. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004; 2: 2152-2155.
- 16 Cushman M, Glynn RJ, Goldhaber SZ. et al. Hormonal factors and risk of recur-rent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost 2006; 4: 2199-2203.
- 17 McRae S, Tran H, Schulman S. et al. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368: 371-378.
- 18 Douketis JD, Kearon C, Bates S. et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Assoc 1998; 279: 458-462.
- 19 Colombus investigators.. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997; 337: 657-662.
- 20 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.